Bromantane Research Overview (also known as Ladasten, N-(2-adamantyl)-2-bromophenylamine, Bromantane HCl)
A stimulant-adaptogen hybrid compound originally developed in Russia. Increases dopamine synthesis and transport while reducing stress-related fatigue through adaptogenic mechanisms. Studied in the context of mental endurance and fatigue resistance.
For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is Bromantane?
Bromantane (Ladasten) is a synthetic adamantane derivative with a unique dual pharmacological profile: it combines dopaminergic stimulation with anxiolytic activity — a combination rarely seen in single compounds. Developed in the Soviet Union as a neuroadaptogen for personnel operating under extreme stress, it has been used clinically in Russia for asthenic conditions and fatigue syndromes.
Mechanism of Action
Bromantane's primary mechanism is the upregulation of dopamine synthesis enzymes — specifically tyrosine hydroxylase (TH) and DOPA decarboxylase — in the dopaminergic pathways of the brain. Unlike classical stimulants that block reuptake or force release, Bromantane increases the capacity to produce dopamine, creating a more sustainable form of dopaminergic enhancement. It also appears to modulate GABA-A receptor sensitivity, contributing to anxiolytic effects without sedation.
Performance and Safety
Animal studies show Bromantane increases exercise tolerance, reduces fatigue, and improves coordination under both physical and cognitive stress. Importantly, it does not produce the cardiovascular effects, appetite suppression, or dependency potential of classical stimulants — making it distinct from conventional psychostimulants.
Quick Reference
| Literature-Reported Dose Range | 50mg once daily |
| Literature-Reported Frequency | Once daily, morning preferred |
| Literature-Reported Cycle Length | 2-4 weeks |
| Literature-Reported Washout | 1-2 weeks between cycles |
| Storage | Room temperature, dry place |
| Timing | Morning dosing; effects build over 7-14 days |
Research Indications
Cognitive
Motivation and Drive Enhancement
Sustained dopamine synthesis upregulation provides stable motivational enhancement without peaks and crashes.
Anti-Fatigue / Anti-Asthenia
Approved in Russia for asthenic disorders with 76% response rate in large clinical trials.
Cognitive Clarity Under Stress
Actoprotector class — enhances mental performance under stress and fatigue without cardiovascular strain.
Anxiolytic
Anxiety Reduction Without Sedation
Demonstrated anxiolytic effects in validated animal models without sedation or cognitive impairment.
Stress Resilience
Modulates HPA axis for improved adaptive stress responses and emotional stability.
Mood Stabilization
Dual dopaminergic and serotonergic synthesis enhancement provides broad-spectrum mood support.
Physical Performance
Physical Performance Enhancement
Premier actoprotector improving endurance and work capacity, particularly under heat stress.
Immune System Support
Enhances phagocytic activity and T-cell function during physical and psychological stress.
Recovery Enhancement
Accelerates recovery from physical exhaustion through improved catecholamine synthesis and HPA axis modulation.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Standard nootropic/anti-asthenia | 50mg | Once daily | Oral |
| Full therapeutic dose | 100mg | Once daily | Oral |
| Conservative start | 25mg | Once daily | Oral |
Timing
Recommended administration window: morning dosing; effects build over 7-14 days. Typical onset: acute: 1.5-2h. Full effects: 7-14 days. Persist 2-4 weeks post-cycle.
Peptide Interactions
Both developed in Russia with complementary anxiolytic mechanisms — Selank via GABAergic modulation, bromantane via dopaminergic enhancement. May provide balanced cognitive and mood support.
Complementary nootropic pathways — Semax enhances BDNF/NGF while bromantane upregulates dopamine synthesis enzymes. Combined cognitive and motivational enhancement.
Different cognitive enhancement mechanisms — Omberacetam modulates glutamate receptors while bromantane enhances dopamine synthesis. Potentially complementary for motivation and memory.
Theoretical risk: bromantane increases dopamine and serotonin synthesis while MAOIs block their breakdown, creating potential for dangerous neurotransmitter accumulation. No clinical cases documented, but mechanism warrants avoidance.
Theoretical concern: bromantane's hepatic metabolism may affect SSRI levels through shared metabolic pathways. No direct interaction studies exist. Monitor for changes in antidepressant efficacy if combining.
Overlapping dopaminergic effects through different mechanisms. Bromantane increases dopamine synthesis while stimulants increase dopamine release/block reuptake. Risk of excessive dopaminergic stimulation.
Different stimulant mechanisms — caffeine blocks adenosine while bromantane upregulates dopamine synthesis. Common combination in biohacking protocols at normal caffeine doses.
Bromantane upregulates TH enzyme which converts L-tyrosine to L-DOPA. Providing adequate substrate (L-tyrosine) may support the enhanced enzymatic capacity.
Reported Research Timeline
01Day 1–3 (reported in cited studies): subtle stimulation and mood lift within 1.5-2 hours
02Week 1 (reported in cited studies): noticeable energy improvement and emerging anxiolytic effects
03Week 2–3 (reported in cited studies): full therapeutic effects from TH/AADC gene expression upregulation
04Week 3–4 (reported in cited studies): peak benefits — stable mood, endurance, cognitive clarity
05Post-cycle: Benefits persist 2-4 weeks after stopping
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Exceptional safety profile: LD50 of 9000 mg/kg (rat), only 3% side effects in 728-patient trial
No tolerance, dependence, or withdrawal documented
Not FDA approved — investigational/research compound
Avoid combining with MAOIs (theoretical risk based on mechanism)
Monitor if combining with SSRIs (theoretical metabolic interaction concern)
Highly lipophilic — accumulates in adipose tissue
Seek Medical Attention If:
Unusual agitation or insomnia
Signs of excessive dopaminergic stimulation
Unexpected mood changes or increased anxiety
Quality Indicators
Verified Marker
White crystalline powder
High-quality bromantane is white to off-white crystalline solid with ≥98% HPLC purity
Acceptable Range
Research chemical status
Not FDA/EMA approved. Available through research suppliers only. Quality varies.
Acceptable Range
WADA prohibited
Banned substance for athletes. Metabolites detectable up to 14 days post-dose.
Quality Concern
Unknown sources
Products without certificates of analysis or from unverified sources pose quality risks.
Research Citations
- Actoprotector Bromantane (Ladasten)
Morozov, I.S., Ivanova, I.A., Lukicheva, T.A., 2001, Bulletin of Experimental Biology and Medicine - Toxic effect of single treatment with bromantane on neurological status of experimental animals
Iezhitsa, I.N., Spasov, A.A., Bugaeva, L.I., 2002, Bulletin of Experimental Biology and Medicine - The effect of bromantane on the dopamine synthesis and metabolism in the rat striatum
Kudrin, V.S., Klodt, P.M., Narkevich, V.B., et al., 2007, Eksperimental'naia i Klinicheskaia Farmakologiia - The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats
Mikhaylova, M.A., Kulikov, A.V., Kudrin, V.S., et al., 2007, Neuropharmacology - The effect of bromantane on the behavior of inbred mouse strains with different phenotypes of emotional stress reaction
Iezhitsa, I.N., Spasov, A.A., Bugaeva, L.I., 1999, Eksperimental'naia i Klinicheskaia Farmakologiia - Pharmacological characteristics of a new actoprotector, bromantane
Bobkov, Yu.G., Morozov, I.S., Glozman, O.M., et al., 1984, Bulletin of Experimental Biology and Medicine - Clinical and pharmacokinetic study of the new psychoactive drug Ladasten
Zherdev, V.P., Neznamov, G.G., Siuniakov, S.A., et al., 2009, Vestnik Rossiiskoi Akademii Meditsinskikh Nauk - Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten
Siuniakov, S.A., Grishin, S.A., Teleshova, E.S., et al., 2011, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova
Research Focus
Dopamine synthesis, Anxiolytic, Cognitive performance, Physical endurance, Neuroadaptogen
Verified Vendors Carrying Bromantane
Frequently Asked Questions
What should researchers watch for with Bromantane?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Bromantane?
Day 1–3 (reported in cited studies): subtle stimulation and mood lift within 1.5-2 hours
How is Bromantane typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →